摘要
Abstract
Objective:To analyze the impact of Bifidobacterium on the efficacy and safety of immunotherapy for advanced liver cancer(HCC).Methods:Forty patients with advanced HCC in the Department of Oncology at the Affiliated Hospital of Chifeng University from August 2022 to January 2023 were collected and randomly divided into two groups.The control group was treated with Xindilizumab injection combined with lenvatinib mesylate,while the observation group was treated with Bifidobacterium in addition to the control group.Observe and compare the changes in gut microbiota composition,tumor volume,IL-6,neutrophil to lymphocyte ratio(NLR),and albumin levels between two groups of patients at different stages、Immune function index.Follow up and observe the total effective rate(ORR),progression-free survival(PFS),and overall survival(OS)of patients,and compare the incidence of adverse reactions between the two groups.Results:There was no significant difference in general information and pathological results between the control group and the observation group(P＞0.05).There was no statistical significance in the expression of bifidobacterium between the two groups before treatment(P＞0.05),but after treatment,the expression of bifidobacterium in the observation group was significantly higher than that in the control group,with statistical significance(P＜0.05).After four cycles of oral bifidobacterium treatment,the levels of IL-6 and NLR in observation group were significantly lower than those in control group,and the level of albumin in observation group was significantly increased,with statistical significance(P＜0.05).In the control group,four patients showed improvement,the effective rate was 20％,while in the observation group,nine patients showed improvement,and the effective rate was 45％.The observed PFS and OS were longer than the control group,and the differences were statistically significant(P＜0.05).There was no significant difference in adverse reactions between the two groups(P＞0.05).After the intervention,the levels of IgA,IgM,IgG,CD3+,CD4+,and CD4+/CD8+in the test group were significantly higher than those in the reference group,with statistical significance(P＜0.05).Conclusion:Bifidobacterium can achieve efficacy sensitization in immunotherapy for patients with advanced HCC without increasing the adverse reactions of treatment,which is expected to provide new treatment ideas for this disease.关键词
肝细胞癌/双歧杆菌/免疫治疗/临床疗效/不良反应Key words
bifidobacterium/liver cancer/immunotherapy/effect/adverse reactions分类
医药卫生
